A Case of Metformin-associated Lactic Acidosis

Hye-Sook CHOI; Kyung-Hwan JUNG; Jae-Jun SHIM; Myung-Jong CHAE; Sang-Ho LEE; Tae-Won LEE; Chun-Kyu LIM; Myung-Jae KIM.
Korean Journal of Nephrology ; : 143-146, 2004.
Artículo en Ko | WPRIM | ID: wpr-204816

Documentos relacionados

  1. Treating Helicobacter pylori infection in the face of growing antibiotic resistance.
  2. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
  3. Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
  4. Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates.
  5. [Inhibitory Effects and Mechanisms of Three Benzodiazepines on <i>Helicobacter pylori</i>].
  6. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
  7. Roles of Lipopolysaccharide Glycosyltransferases in Maintenance of <i>Helicobacter pylori</i> Morphology, Cell Wall Permeability, and Antimicrobial Susceptibilities.
  8. [Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province].
  9. 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: Real-world evidence.
  10. Prevalence of antibiotic heteroresistance associated with Helicobacter pylori infection: A systematic review and meta-analysis.